GHK-Cu + hyaluronic acid : Compatible
If we start bypassing the evidence threshold for approval, where does it end
What weight loss outcome does the platform reference
Liquid Biopsy
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies
More research is needed to determine the best approach to monitoring and managing these patients once the medication is discontinued. According to Maya and colleagues, current evidence on links between GLP-1s and pregnancy complications remain limited, conflicting and subject to residual confounding by indication or selection and recall bias. They added that if gestational weight gain is a result of GLP-1 discontinuation before or early during pregnancy, negative outcomes for the parent-child dyad could result. In the retrospective analysis, the researchers assessed outcomes among 149,790 singleton pregnancies delivered between June 1, 2016, and March 31, 2025
